Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normalTPMTgenotype-Reference-Cited by-同舟云学术

Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normalTPMTgenotype

Published:2017-09-15 Issue:10 Volume:46 Page:953-963
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Broekman M. M. T. J.¹^ORCID,Coenen M. J. H.²,Wanten G. J.¹,van Marrewijk C. J.²,Klungel O. H.³,Verbeek A. L. M.⁴,Hooymans P. M.⁵,Guchelaar H.-J.⁶,Scheffer H.²,Derijks L. J. J.⁷^ORCID,Wong D. R.⁵^ORCID,de Jong D. J.¹

Affiliation:

1. Department of Gastroenterology; Radboud Institute for Molecular Life Sciences; Radboud University Medical Center; Nijmegen The Netherlands

2. Department of Human Genetics; Radboud Institute for Health Sciences; Radboud University Medical Center; Nijmegen The Netherlands

3. Department of Pharmacoepidemiology and Pharmacotherapy; Utrecht University; Utrecht The Netherlands

4. Department for Health Evidence; Radboud University Medical Center; Nijmegen The Netherlands

5. Department of Clinical Pharmacy, Pharmacology and Toxicology; Zuyderland Medical Center; Sittard-Geleen The Netherlands

6. Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden The Netherlands

7. Department of Clinical Pharmacy; Máxima Medical Center; Veldhoven The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14323/fullpdf

Reference58 articles.

1. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy;Colombel;Gastroenterology,2000

2. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease;Strik;Aliment Pharmacol Ther,2017

3. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014;Kirchgesner;Aliment Pharmacol Ther,2017

4. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review;Gisbert;The American journal of gastroenterology,2008

5. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease;Hindorf;Aliment Pharmacol Ther,2006

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors for liver, blood and kidney adverse events from glucocorticoid sparing immune-suppressing drugs in immune-mediated inflammatory diseases: a prognostic systematic review;RMD Open;2024-01

2. Comparing Myelosuppression Frequency in Indian Inflammatory Bowel Disease Patients: A Randomized Trial of Full Dose Versus Gradual Escalation of Thiopurines;Cureus;2023-12-22

3. Association of <i>NUDT15</i> gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis;Haematologica;2023-10-05

4. Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation;eClinicalMedicine;2023-10

5. Safety and efficacy of personalized versus standard initial dosing of thiopurines: Systematic review and meta-analysis of randomized trials;Expert Opinion on Drug Safety;2023-07-18